Lilly Buys Loxo, Baselga Resurfaces, and Bluebird’s Gene Therapy Payment Plan

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches
AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat
Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie